Martina Porter is a Dermatology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 128 publications with 1,048 citations (h-index 17); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave
Boston, MA 022155491
Telephone
617-667-4995Provider last certified this registry record 18 Nov 2025.
Clinical trials
- The Safety and Efficacy of Roflumilast Foam in HS
Sponsor: Beth Israel Deaconess Medical Center
- Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
Sponsor: Beth Israel Deaconess Medical Center
- Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
Sponsor: Beth Israel Deaconess Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202518 payments$31,130openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year202521 payments$15,353openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20254 payments$12,639openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.8%Interleukin-17A Antagonist16.4%Cosentyx Sensoready (2 Pens)56%Cosentyx Unoready Pen26%Taltz Autoinjector18%Part D<11 patientsTNF inhibitor11.6%Humira(Cf) Pen100%Part D<11 patients+ 4 more classes in this area
Dermatology
19.9%Interleukin-4 Receptor alpha Antagonist8.6%Dupixent Syringe59%Dupixent Pen41%Part D<11 patientsCorticosteroid4.8%Triamcinolone Acetonide100%Part D≥13 patients+ 2 more classes in this area
Sensory organs
14.8%Corticosteroid14.8%Hydrocortisone29%Clobetasol Propionate27%Betamethasone Dipropionate22%Betamethasone Diprop Augmented22%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hidradenitis Suppurativa: New Targets and Emerging Treatments
American Journal of Clinical Dermatology
2024 - Biologics in hidradenitis suppurativa: Progress and new directions
Journal of the American Academy of Dermatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”